GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001619715 | Esophagus | ESCC | endosomal transport | 168/8552 | 230/18723 | 2.28e-17 | 1.93e-15 | 168 |
GO:0090150110 | Esophagus | ESCC | establishment of protein localization to membrane | 182/8552 | 260/18723 | 1.27e-15 | 8.19e-14 | 182 |
GO:0072659110 | Esophagus | ESCC | protein localization to plasma membrane | 193/8552 | 284/18723 | 1.95e-14 | 1.03e-12 | 193 |
GO:199077819 | Esophagus | ESCC | protein localization to cell periphery | 217/8552 | 333/18723 | 4.08e-13 | 1.88e-11 | 217 |
GO:009887615 | Esophagus | ESCC | vesicle-mediated transport to the plasma membrane | 99/8552 | 136/18723 | 1.13e-10 | 3.39e-09 | 99 |
GO:003150314 | Esophagus | ESCC | protein-containing complex localization | 139/8552 | 220/18723 | 1.14e-07 | 1.85e-06 | 139 |
GO:004311218 | Esophagus | ESCC | receptor metabolic process | 104/8552 | 166/18723 | 7.44e-06 | 7.37e-05 | 104 |
GO:006195114 | Esophagus | ESCC | establishment of protein localization to plasma membrane | 44/8552 | 60/18723 | 1.25e-05 | 1.15e-04 | 44 |
GO:00324565 | Esophagus | ESCC | endocytic recycling | 51/8552 | 73/18723 | 2.47e-05 | 2.10e-04 | 51 |
GO:00019192 | Esophagus | ESCC | regulation of receptor recycling | 19/8552 | 23/18723 | 3.12e-04 | 1.85e-03 | 19 |
GO:00018813 | Esophagus | ESCC | receptor recycling | 25/8552 | 33/18723 | 4.30e-04 | 2.43e-03 | 25 |
GO:00019211 | Esophagus | ESCC | positive regulation of receptor recycling | 12/8552 | 14/18723 | 2.51e-03 | 1.08e-02 | 12 |
GO:009015018 | Oral cavity | OSCC | establishment of protein localization to membrane | 163/7305 | 260/18723 | 7.13e-15 | 4.47e-13 | 163 |
GO:007265918 | Oral cavity | OSCC | protein localization to plasma membrane | 169/7305 | 284/18723 | 1.69e-12 | 7.21e-11 | 169 |
GO:00161979 | Oral cavity | OSCC | endosomal transport | 141/7305 | 230/18723 | 5.40e-12 | 2.06e-10 | 141 |
GO:199077816 | Oral cavity | OSCC | protein localization to cell periphery | 190/7305 | 333/18723 | 1.46e-11 | 5.13e-10 | 190 |
GO:00315034 | Oral cavity | OSCC | protein-containing complex localization | 123/7305 | 220/18723 | 2.54e-07 | 4.00e-06 | 123 |
GO:00988769 | Oral cavity | OSCC | vesicle-mediated transport to the plasma membrane | 79/7305 | 136/18723 | 4.93e-06 | 5.58e-05 | 79 |
GO:00619518 | Oral cavity | OSCC | establishment of protein localization to plasma membrane | 39/7305 | 60/18723 | 4.07e-05 | 3.53e-04 | 39 |
GO:004311210 | Oral cavity | OSCC | receptor metabolic process | 88/7305 | 166/18723 | 1.68e-04 | 1.15e-03 | 88 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
NSG1 | SNV | Missense_Mutation | novel | c.11N>C | p.Leu4Ser | p.L4S | P42857 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
NSG1 | SNV | Missense_Mutation | rs756755886 | c.184N>T | p.Arg62Cys | p.R62C | P42857 | protein_coding | deleterious(0.04) | probably_damaging(0.983) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
NSG1 | SNV | Missense_Mutation | novel | c.301N>T | p.Val101Phe | p.V101F | P42857 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
NSG1 | SNV | Missense_Mutation | | c.539N>A | p.Ala180Glu | p.A180E | P42857 | protein_coding | tolerated_low_confidence(0.34) | possibly_damaging(0.751) | TCGA-B5-A0K4-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | SD |
NSG1 | SNV | Missense_Mutation | | c.239G>T | p.Arg80Met | p.R80M | P42857 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-EO-A22U-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
NSG1 | SNV | Missense_Mutation | novel | c.442N>C | p.Asn148His | p.N148H | P42857 | protein_coding | deleterious(0.01) | possibly_damaging(0.73) | TCGA-EO-A3B0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
NSG1 | SNV | Missense_Mutation | rs755840500 | c.221N>T | p.Thr74Met | p.T74M | P42857 | protein_coding | tolerated(0.22) | possibly_damaging(0.537) | TCGA-EY-A2OP-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
NSG1 | SNV | Missense_Mutation | novel | c.286N>A | p.Cys96Ser | p.C96S | P42857 | protein_coding | tolerated(0.07) | probably_damaging(0.999) | TCGA-2Y-A9H9-01 | Liver | liver hepatocellular carcinoma | Male | >=65 | I/II | Targeted Molecular therapy | sorafenib | PD |
NSG1 | SNV | Missense_Mutation | | c.281N>G | p.Leu94Arg | p.L94R | P42857 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-55-8092-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
NSG1 | SNV | Missense_Mutation | | c.373N>A | p.Pro125Thr | p.P125T | P42857 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-69-7765-01 | Lung | lung adenocarcinoma | Male | <65 | III/IV | Chemotherapy | carboplatin | SD |